Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 10:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 33,121 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Safety and Pharmacokinetics of KSP-1007 Alone and Coadministered With Meropenem in Healthy Subjects

NCT05226923
View directory record Official record
Conditions
Bacterial Infections
Interventions
KSP-1007, Placebo:0.9% sodium chloride, Meropenem
Drug · Other
Lead sponsor
Sumitovant Biopharma, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Oct 31, 2026, 10:29 PM EDT
Completed Not applicable Interventional Results available

Probiotics and Antibiotic Associated Diarrhea in Pediatric Complicated Appendicitis

NCT04529980
View directory record Official record
Conditions
Appendicitis, Appendicitis; Perforation
Interventions
Lactobacillus rhamnosus GG (LGG) Probiotic, Placebo
Dietary Supplement
Lead sponsor
Children's Health
Other
Eligibility
4 Years to 18 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Oct 31, 2026, 10:29 PM EDT
Not listed Phase 2Phase 3 Interventional

Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder

NCT05637879
View directory record Official record
Conditions
PTSD
Interventions
Glecaprevir/pibrentasvir, Placebo
Drug · Other
Lead sponsor
White River Junction Veterans Affairs Medical Center
Federal
Eligibility
19 Years to 70 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
White River Junction, Vermont
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 31, 2026, 10:29 PM EDT
Completed Phase 3 Interventional Results available

Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)

NCT04233879
View directory record Official record
Conditions
HIV-1 Infection
Interventions
DOR/ISL, BIC/FTC/TAF, Placebo to BIC/FTC/TAF, Placebo to DOR/ISL
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
17
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 31, 2026, 10:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety Study of Recombinant M2e Influenza-A Vaccine in Healthy Adults

NCT00819013
View directory record Official record
Conditions
Influenza
Interventions
Influenza A Vaccine: ACAM FLU-A, Saline placebo
Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 40 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
3
States / cities
Miami, Florida • Lenexa, Kansas • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jan 19, 2012 · Synced Oct 31, 2026, 10:29 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Investigating the Anti-Human Immunodeficiency Virus (HIV) & Anti-inflammatory Effect of Chloroquine

NCT00308620
View directory record Official record
Conditions
HIV Infections
Interventions
chloroquine phosphate, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Oct 31, 2026, 10:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to the Experimental Preventive HIV Vaccine, EP HIV-1090, in Healthy, HIV-1 Uninfected Adults

NCT00141024
View directory record Official record
Conditions
HIV Infections
Interventions
EP HIV-1043, EP HIV-1090
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
3
States / cities
San Francisco, California • Baltimore, Maryland • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 31, 2026, 10:29 PM EDT
Completed Phase 1 Interventional Results available

Opioid and Cannabinoid Interactions

NCT03705559
View directory record Official record
Conditions
Marijuana Usage, Opioid Use
Interventions
Vaporized Marijuana, Opioid Agonist, Placebo
Drug
Lead sponsor
Shanna Babalonis, PhD
Other
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Oct 31, 2026, 10:29 PM EDT
Terminated Phase 3 Interventional Results available

Locally Applied Antibiotics for Infection Prophylaxis in Treatment of Open Fractures

NCT03705962
View directory record Official record
Conditions
Fractures, Open
Interventions
Tobramycin, Placebo: normal saline
Drug · Other
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 70 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 31, 2026, 10:29 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Progesterone for Maintenance Tocolysis: A Randomized Placebo Controlled Trial

NCT00946088
View directory record Official record
Conditions
Pregnancy Complications
Interventions
Progesterone, Polyethylene glycol&hydrogenated vegetable oil.
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Oct 31, 2026, 10:29 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of Ciprofloxacin (Inhaled) in Patients With Cystic Fibrosis

NCT00645788
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ciprofloxacin (Cipro Inhale, BAYQ3939), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
12 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
58
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 31, 2026, 10:29 PM EDT
Completed Phase 3 Interventional

Galantamine Versus Placebo in Childhood Autism

NCT00252603
View directory record Official record
Conditions
Autism, Childhood Autism
Interventions
Galantamine
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
5 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 29, 2007 · Synced Oct 31, 2026, 10:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability, PK, ECG Effects, Food Effect, and Drug-drug Interaction (DDI) of Hormonal Contraceptives of PTI-428 in Healthy Female Volunteers

NCT02846142
View directory record Official record
Conditions
Healthy Volunteer
Interventions
PTI-428, Placebo, ethinyl estradiol and levonorgestrel
Drug · Other
Lead sponsor
Proteostasis Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Oct 31, 2026, 10:29 PM EDT
Terminated Phase 3 Interventional

Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes

NCT00263042
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Rimonabant, Placebo (for Rimonabant)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
55 Years and older
Enrollment
18,695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 20, 2016 · Synced Oct 31, 2026, 10:29 PM EDT
Completed Phase 2 Interventional Results available

Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy

NCT05065970
View directory record Official record
Conditions
Immunoglobulin A (IgA) Nephropathy
Interventions
Felzartamab, Placebo
Drug · Other
Lead sponsor
HI-Bio, A Biogen Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Oxnard, California • Vacaville, California • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 31, 2026, 10:29 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease

NCT05136170
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Cenegermin, Vehicle
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
7
States / cities
Glendale, California • Baltimore, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 31, 2026, 10:29 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Abscisic Acid Effects on Glucose Homeostasis and Insulin Sensitivity

NCT04722354
View directory record Official record
Conditions
Pre Diabetes
Interventions
Hyperinsulemic euglycemic clamp, Muscle Biopsy, Oral abscisic acid (ABA), Placebo
Other · Procedure · Dietary Supplement
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 31, 2026, 10:29 PM EDT
Terminated Phase 4 Interventional

Cilostazol and Nimodipine Combined Therapy After Aneurysmal Subarachnoid Hemorrhage (aSAH)

NCT04148105
View directory record Official record
Conditions
Aneurysmal Subarachnoid Hemorrhage
Interventions
Cilostazol 100 MG, Placebo
Drug · Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 100 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Southfield, Michigan
Source: ClinicalTrials.gov public record
Updated May 31, 2024 · Synced Oct 31, 2026, 10:29 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)

NCT01307423
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Apremilast 20mg, Apremilast 30mg, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
30
States / cities
Phoenix, Arizona • Palm Desert, California • Doral, Florida + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Oct 31, 2026, 10:29 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Use of Nicotine Pouches Among Daily Smokers

NCT06043362
View directory record Official record
Conditions
Tobacco Dependence
Interventions
0 mg nicotine pouch, 3 mg nicotine pouch, 6 mg nicotine pouch, Smooth nicotine pouch, Wintergreen nicotine pouch
Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
21 Years to 70 Years
Enrollment
375 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
2
States / cities
Hershey, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 31, 2026, 10:29 PM EDT
Completed Not applicable Interventional Results available

Effect of Metformin on Insulin Sensitivity and Pan-Arterial Vascular Function in Adults With Metabolic Syndrome

NCT02633488
View directory record Official record
Conditions
Metabolic Syndrome, Insulin Sensitivity
Interventions
Placebos, metformin
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 60 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Oct 31, 2026, 10:29 PM EDT
Terminated Phase 3 Interventional

Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing Statins in Patients With Primary Hypercholesterolemia

NCT00729027
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
25 mg/day AVE5530, 50 mg/day AVE5530, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
1,015 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Oct 31, 2026, 10:29 PM EDT
Not listed Phase 2 Interventional

Study to Reinforce Immunity (STRI) Phase 2 Clinical Trial

NCT05046561
View directory record Official record
Conditions
Covid19
Interventions
STRI Formula, Placebo
Drug
Lead sponsor
Eyecheck, Inc.
Industry
Eligibility
18 Years and older
Enrollment
598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
13
States / cities
Coral Gables, Florida • Doral, Florida • Medley, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2022 · Synced Oct 31, 2026, 10:29 PM EDT
Completed Phase 4 Interventional Results available

Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)

NCT00617305
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Ambrisentan, Placebo, Sildenafil, Tadalafil
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
16 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
30
States / cities
Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 31, 2026, 10:29 PM EDT